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It was necessary to exceed the stomach V50Gy constraint 
(usual limit <16cc) in order to achieve coverage in the five 
3D-CRT plans with the largest volumes of PTV-stomach 
overlap. There was a strong correlation between the volume 
of PTV-stomach overlap and stomach V50Gy (Spearman's rho: 
0.97, p<0.001). Stomach V50Gy was also exceeded in the five 
corresponding VMAT 54Gy plans. Where PTV-stomach overlap 
exceeded 15cc, then 3D-CRT and VMAT 54Gy plans could not 
be created without exceeding stomach constraints. The 
different coverage requirements, however, allowed all 
stomach constraints to be met in all but one VMAT 59.4Gy 
plans. Compared to 3D-CRT plans, VMAT 54Gy plans resulted 
in significant reductions in small bowel V50Gy, left and right 
kidney V20Gy, mean liver dose and duodenal V50Gy (Table 
1). There was a small but statistically significant increase in 
PTV mean dose with VMAT 54Gy compared to 3D-CRT (Table 
1) and there was, unsurprisingly, a significant increase in PTV 
mean dose when prescribing VMAT 59.4Gy compared to VMAT 
54Gy (VMAT 59.4Gy vs VMAT 54Gy: 57.7Gy vs 54.1Gy, p<0.001 
(median values)). 
  
 
 
Conclusions: VMAT improved dose sculpting, thereby 
providing dosimetric advantages in several normal tissues and 
a potential solution in cases where constraints were not met 
using 3D-CRT. Volumes of PTV-duodenal and PTV-stomach 
overlap may be useful indicators as to the feasibility of 3D-
CRT planning. Because of lower coverage requirements in 
areas of PTV overlap, escalation to 59.4Gy using VMAT was 
feasible in most cases, facilitating higher mean PTV doses 
while still respecting normal tissue constraints.  
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Purpose/Objective: In 2008 we developed an off line set-up 
verification protocol for breast cancer patients with external 
skin markers [Van der Salm Radiother. Oncol. 90] using MV 
imaging, followed by online set-up correction in 2012 using 
KV imaging. However, we noticed an increase in skin reaction 
localized to the skin markers. Therefore we evaluated the 
feasibility of online setup correction with surgical clips 
evaluating dose coverage of breast and boost area. 
Materials and Methods: In 34 breast cancer patients an 
online set-up correction was performed using the external 
skin marker technique. Set-up correction was performed 
based on the match between a pair of orthogonal KV images 
with DRRs of the planning CT scan, based upon contoured 
skin markers and anatomical landmarks (eg. thoracic wall). In 
retrospect, all images were re-matched with DRRs with 
contoured surgical clips in the post-operative breast. In 
addition, for each patient 3 Cone Beam CTs (CBCT) were 
available. At first we investigated the migration of the 
surgical clips for set-up verification by measuring the inter-
clip distances at the beginning, middle and end of treatment 
on a CBCT with the planning CT as a reference. We then 
compared the setup as determined from the clips with that 
from our skin markers in 5 fractions for each patient (total 
170 fractions). Finally, we looked at the breast CTV coverage 
by recalculating the dose on the online setup corrected CBCT 
(including a re-contoured breast and boost CTV) with the 
patient setup according to both setup techniques. This 
coverage was compared with that of the treatment plan. 
Results: Almost all types of surgical clips could be well 
visualized: 4.7 (sd 0.7 range 3-6) clips per patient were 
available for analysis. Analysis of the interclip distance 
showed that the clip to center-of-mass (COM) distance 
decreased on average by 2 (sd 1) mm (absolute distance clip-
COM: 15(sd 8) mm). Differences between clip and marker 
setup were generally small (avg<0.3mm in all directions). The 
reconstructed dose distributions on the CBCT showed that the 
coverage (95% isodose) of the breast was 99% in the 
treatment plan, and remained 99% for the skin marker as well 
as for the surgical clip technique. Also the boost area 
coverage remained at 99% for both techniques and the 
treatment plan. Some differences in rotation (max 2 degr.) 
setup were observed between clip and skin marker 
technique, but in light of conservation of coverage those 
differences were indicated as not clinically relevant. 
Conclusions: The use of surgical clips for online position 
verification/correction using orthogonal-pair KV imaging 
results in as good target coverage as the use of skin markers, 
even though there is some migration of the clips. The use of 
surgical clips provides a simpler solution for position 
verification as compared to our skin markers, without the 
disadvantage of local increase of skin dose.  
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Purpose/Objective: Radiotherapy (RT) is a valuable 
treatment modality for potential cure and palliation, for 
patients with lung cancer. Reports have established that RT is 
greatly underutilised in Australia, presumably due to 
geographic and economic factors. In a public private 
partnership (PPP) between Radiation Oncology Queensland 
(ROQ) and the Queensland State Government, a no patient 
cost (NPC) RT centre was established in 2013. Prior to the 
establishment of ROQ at the Gold Coast University Hospital, 
patients were required to travel 70km for an NPC service. 
The Aim of this study was to investigate the impact of a PPP 
RT centre, with on-site radiation oncologists, on RT 
utilisation rates and delays to commencement of RT, 
compared to immediate historical figures of when patients 
were required to travel for no cost RT.  
Materials and Methods: Queensland Oncology Online 
database was used to identify patients with a new diagnosis 
of or new problem relating to Small Cell or Non Small Cell 
Lung Cancer. All such patients discussed at the Gold Coast 
University Hospital Lung Multi-disciplinary Meeting between 
the dates of 17th June 2013 and 17th Jun 2014, were included 
for analysis. The first RT simulation at ROQ was performed on 
17 December 2013: all patient problems discussed 6 months 
prior to this were classified as Pre ROQ, and those discussed 
from 17 December onwards as Post ROQ. Electronic records 
were accessed to determine which patients had received RT, 
the indication, date of referral and the date of first RT 
fraction. Primary end points were indication-based utilisation 
rates, as well as time from referral to commencement of RT. 
Evidence-based indications for RT in lung cancer include: 
curative intent, palliation of bone and brain metastases and 
palliation of symptomatic thoracic disease.  
Results: A total of 158 patients (Pre ROQ 77 v Post ROQ 81) 
were identified for the study. There were no significant 
demographic differences between the Pre ROQ and Post ROQ 
groups. A statistically significant increase in indication-based 
utilisation was noted (83% v 98% p = 0.03). Pre ROQ, the most 
common under-referred indications were palliation of 
symptomatic thoracic disease and bone metastasis. A 
statistically significant reduction in mean time to 
commencement of RT was also noted following the 
introduction of ROQ (23 days v 27 days p = 0.03).  
Conclusions: The introduction of the first PPP RT Centre in 
Australia’s fifth largest city has lead to increased indication-
based RT utilisation rates and shorter waiting times for 
patients with lung cancer. 
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Purpose/Objective: Radiotherapy (RT) Quality Assurance 
(QA) is an essential component of a clinical trial to ensure 
standardised treatment. It is unclear if there is scope to risk 
adapt QA intensity. We explore the site- and clinician-level 
factors which are associated with Real Time Review (RTR) 
resubmission to help tailor future QA protocols. 
Materials and Methods: RAVES is a randomised trial 
comparing adjuvant with early salvage RT in men with 
positive surgical margins or pT3 disease following radical 
prostatectomy. QA in RAVES requires each clinician and site 
to submit a credentialing dummy-run (DR) and for each 
patient RT plan to undergo external RTR prior to commencing 
treatment. Prospectively defined major violations from trial 
protocol required remedy and resubmission prior to starting 
treatment. Reports from DR and RTRs were collated and 
violations were categorised into target volume contouring, 
critical structure contouring, dosimetric or other.Site and 
clinician factors associated with RTR resubmission were 
examined using hierarchical modelling. These included: 
incidence of DR resubmission, number of cases per clinician 
and site, time between initial credentialing and RTR, and RT 
technique (3DCRT v IMRT).  
Results: Data were collected from 171 consecutive patients, 
treated by 46 clinicians at 32 hospitals between June 2009 
and October 2014. There were 47 RTR resubmissions (27% of 
all cases) and 65 major violations in total. The majority of 
resubmissions were due to contouring (39/65) or dosimetric 
violations (22/65). The majority of contouring violations 
(90%) related to target volumes (CTV and PTV). Significant 
decreases in RTR resubmissions were seen at both clinician 
and site level for each additional patient accrued. For each 
additional case submitted, the relative risk of resubmission 
decreased by 25% at the clinician level (Hazard Ratio [HR] 
0.75, p=0.02) and by 28% by site (HR 0.72, p=0.01). The rate 
of resubmission dropped from 40% for first patient submitted 
from each clinician or site to 20% after ≥5 patients. Use of 
IMRT was associated with lower rate of resubmission 
compared to 3DCRT (HR 0.38, p=0.05). At site level, rate of 
resubmission due to dosimetric violation after first five 
submissions was only 2% (2/103). For a clinician, a DR 
resubmission was correlated with a non-statistically 
significant 59% increase in the relative risk of a subsequent 
RTR resubmission (Adjusted HR 1.59, p>0.1). The lowest risk 
for resubmission were clinicians that did not need DR or first 
RTR resubmission (17%) compared to high risk group that 
needed both resubmitted (44%). 
